Skip to main content
. Author manuscript; available in PMC: 2016 Jul 22.
Published in final edited form as: Med Oncol. 2016 Jan 9;33(2):13. doi: 10.1007/s12032-015-0728-2

Table 4.

Toxicities for which Dose Adjustment or Drug Discontinuation Occurred

Patient # Starting Dose Toxicities (Grade) Dose Reduced To
2 200mg/m2 every 21 days Fatigue (Grade 2) 200mg/m2 every 28 days
4 260mg/m2 every 21 days Facial Edema (Grade 2) 260mg/m2 every 28 days
9 200mg/m2 every 21 days Peripheral Sensory Neuropathy (Grade 3) Drug Discontinued
10 260mg/m2 every 21 days Arthralgias/Myalgias (Grade 3) Drug Discontinued
13 260mg/m2 every 21 days Fatigue (Grade 3) 200mg/m2 every 28 days
16 200mg/m2 every 21 days Fatigue (Grade 3)
Arthralgias/Myalgias (Grade 2)
Peripheral Sensory Neuropathy (Grade 2)		 160mg/m2 every 28 days
21 200mg/m2 every 21 days Peripheral Sensory Neuropathy (Grade 2) 200mg/m2 every 28 days
26 200mg/m2 every 21 days Fatigue (Grade 2) 150mg/m2 every 28 days
30 230mg/m2 every 21 days Anemia (Grade 2) 230mg/m2 every 28 days
31 260mg/m2 every 21 days Fatigue (Grade 2)
Peripheral Sensory Neuropathy (Grade 2)		 200mg/m2 every 28 days